Skip to main content
Quest Diagnostics

The Symptom Burden of Women With a Known Risk of Breast Cancer Receiving Risk Reducing Medication

The Symptom Burden of Women With a Known Risk of Breast Cancer Receiving Risk Reducing Medication

Authors: Whisenant MS, Jones JT, Gonzalez AO, Bevers TB, Brassil K, Ponce DA, Kamat S, Solis E, Maliackal A, Warlick H, Walters A, Denham C, Williams LA

Citation: Cancer Treat Res Commun. 2023 Dec 20;43:100784. doi: 10.1016/j.ctarc.2023.100784. Online ahead of print.

Specialties: Oncology

Disclaimer: One or more of the authors of this publication were employed at the time by PackHealth, a subsidiary of Quest Diagnostics.

Related content

Audio Podcast
A Commitment to Women’s Health
Audio Podcast
Women’s Heart Health: Unique Cardiometabolic Risks
Test FAQ
BRCA1 and BRCA2 tests
Publication
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
Publication
Probing the Relevance of BRCA1 and BRCA2 Germline Pathogenic Variants Beyond Breast and Ovarian Cancer
Test FAQ
Comprehensive Hereditary Cancer Panel
Test FAQ
BRCA Panel Plus

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.